Genotype-proteotype linkage in the Wiskott-Aldrich syndrome

Journal of Immunology

Volumn 175, Issue 2, 2005, Pages 1329-1336

  Lutskiy, Maxim I ^a   Rosen, Fred S ^a   Remold O'Donnell, Eileen ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CENTER FOR BLOOD RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSKELETON PROTEIN; MESSENGER RNA; PROLINE; UNCLASSIFIED DRUG; WAS PROTEIN;

ALTERNATIVE RNA SPLICING; ARTICLE; BINDING SITE; CLINICAL ARTICLE; DISEASE COURSE; EVH1 DOMAIN; FRAMESHIFT MUTATION; GENE MUTATION; GENOTYPE; GENOTYPE PROTEOTYPE LINKAGE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; MALE; MISSENSE MUTATION; NONSENSE MUTATION; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONTENT; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN VARIANT; PROTEOTYPE; THROMBOCYTOPENIA; TREATMENT PLANNING; WISKOTT ALDRICH SYNDROME; X CHROMOSOME LINKED DISORDER; X CHROMOSOME LINKED THROMBOCYTOPENIA;

EID: 23244465352     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.2.1329     Document Type: Article

References (43)

1. Wiskott, A. 1937. Familiarer, angeobren Morbus Werlhofi? Monatschrift Kinderheil 68: 212-216.
2. Perry, G. S., 3rd, B. D. Spector, L. M. Schuman, J. S. Mandel, V. E. Anderson, R. B. McHugh, M. R. Hanson, S. M. Fahlstrom, W. Krivit, and J. H. Kersey. 1980. The Wiskott-Aldrich syndrome in the United States and Canada (1892-1979). J. Pediatr. 97: 72-78.
3. Sullivan, K. E., C. A. Mullen, R. M. Blaese, and J. A. Winkelstein. 1994. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J. Pediatr. 125: 876-885.
4. Zhu, Q., C. Watanabe, T. Liu, D. Hollenbaugh, R. M. Blaese, S. B. Kanner, A. Aruffo, and H. D. Ochs. 1997. Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype. Blood 90: 2680-2689.
5. Ochs, H. D., and F. S. Rosen. 1999. The Wiskott-Aldrich syndrome. In Primary Immunodeficiency Diseases. H. D. Ochs, C. I. E. Smith, and J. M. Puck. Oxford University Press, New York, pp. 292-305.
6. Filipovich, A. H., J. V. Stone, S. C. Tomany, M. Ireland, C. Kollman, C. J. Pelz, J. T. Casper, M. J. Cowan, J. R. Edwards, A. Fasth, et al. 2001. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood 97: 1598-1603.
7. Derry, J. M., H. D. Ochs, and U. Francke. 1994. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell 78: 635-644.
8. Miki, H., T. Sasaki, Y. Takai, and T. Takenawa. 1998. Induction of filopodium formation by a WASP-related actin-depolymerizing protein N-WASP. Nature 391: 93-96.
9. Rohatgi, R., H. Y. Ho, and M. W. Kirschner. 2000. Mechanism of N-WASP activation by CDC42 and phosphatidylinositol 4,5-bisphosphate. J. Cell Biol. 150: 1299-1310.
10. Kim, A. S., L. T. Kakalis, N. Abdul-Manan, G. A. Liu, and M. K. Rosen. 2000. Autoinhibition and activation mechanisms of the Wiskott-Aldrich syndrome protein. Nature 404: 151-158.
11. Sasahara, Y., R. Rachid, M. J. Byrne, M. A. de la Fuente, R. T. Abraham, N. Ramesh, and R. S. Geha. 2002. Mechanism of recruitment of WASP to the immunological synapse and of its activation following TCR ligation. Mol. Cell 10: 1269-1281.
12. Volkman, B. F., K. E. Prehoda, J. A. Scott, F. C. Peterson, and W. A. Lim. 2002. Structure of the N-WASP EVH1 domain-WIP complex: insight into the molecular basis of Wiskott-Aldrich Syndrome. Cell 111: 565-576.
13. Kwan, S. P., T. L. Hagemann, R. M. Blaese, A. Knutsen, and F. S. Rosen. 1995. Scanning of the Wiskott-Aldrich syndrome (WAS) gene: identification of 18 novel alterations including a possible mutation hotspot at Arg86 resulting in thrombocytopenia, a mild WAS phenotype. Hum. Mol. Genet 4: 1995-1998.
14. Lemahieu, V., J. M. Gastier, and U. Francke. 1999. Novel mutations in the Wiskott-Aldrich syndrome protein gene and their effects on transcriptional, translational, and clinical phenotypes. Hum. Mutat. 14: 54-66.
15. Remold-O'Donnell, E., J. Cooley, A. Shcherbina, T. L. Hagemann, S. P. Kwan, D. M. Kenney, and F. S. Rosen. 1997. Variable expression of WASP in B cell lines of Wiskott-Aldrich syndrome patients. J. Immunol. 158: 4021-4025.
16. Wengler, G. S., L. D. Notarangelo, S. Berardelli, G. Pollonni, P. Mella, A. Fasth, A. G. Ugazio, and O. Parolini. 1995. High prevalence of nonsense, frame shift, and splice-site mutations in 16 patients with full-blown Wiskott-Aldrich syndrome. Blood 86: 3648-3654.
17. Schindelhauer, D., M. Weiss, H. Hellebrand, A. Golla, M. Hergersberg, R. Seger, B. H. Belohradsky, and A. Meindl. 1996. Wiskott-Aldrich syndrome: no strict genotype-phenotype correlations but clustering of missense mutations in the amino-terminal part of the WASP gene product. Hum. Genet. 98: 68-76.
18. Greer, W. L., A. Shehabeldin, J. Schulman, A. Junker, and K. A. Siminovitch. 1996. Identification of WASP mutations, mutation hotspots and genotype-phenotype disparities in 24 patients with the Wiskott-Aldrich syndrome. Hum. Genet. 98: 685-690.
19. Kenney, D. M. 1990. Wiskott-Aldrich syndrome and related X-linked thrombocytopenia. Curr. Opin. Pediatr. 2: 931-934.
20. Shcherbina, A., F. S. Rosen, and E. Remold-O'Donnell. 1999. WASP levels in platelets and lymphocytes of Wiskott-Aldrich syndrome patients correlate with cell dysfunction. J. Immunol. 163: 6314-6320.
21. Jones, L. N., M. I. Lutskiy, J. Cooley, D. M. Kenney, F. S. Rosen, and E. Remold-O'Donnell. 2002. A novel protocol to identify mutations in patients with Wiskott-Aldrich syndrome. Blood Cells Mol. Dis. 28: 392-398.
22. Halford, W. P., V. C. Falco, B. M. Gebhardt, and D. J. Carr. 1999. The inherent quantitative capacity of the reverse transcription-polymerase chain reaction. Anal. Biochem. 266: 181-191.
23. Thrasher, A. J. 2002. WASp in immune-system organization and function. Nat. Rev. Immunol. 2: 635-646.
24. Rees, D. D., R. A. Rogers, J. Cooley, R. J. Mandle, D. M. Kenney, and E. Remold-O'Donnell. 1999. Recombinant human monocyte/neutrophil elastase inhibitor protects rat lungs against injury from cystic fibrosis airway secretions. Am. J. Respir. Cell Mol. Biol. 20: 69-78.
25. Silverman, G. A., P. I. Bird, R. W. Carrell, F. C. Church, P. B. Coughlin, P. G. Gettins, J. A. Irving, D. A. Lomas, C. J. Luke, R. W. Moyer, et al. 2001. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins: evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J. Biol. Chem. 276: 33293-33296.
26. Kwan, S. P., T. L. Hagemann, B. E. Radtke, R. M. Blaese, and F. S. Rosen. 1995. Identification of mutations in the Wiskott-Aldrich syndrome gene and characterization of a polymorphic dinucleotide repeat at DXS6940, adjacent to the disease gene. Proc. Natl. Acad. Sci. USA 92: 4706-4710.
27. Lutskiy, M. I., Y. Sasahara, D. M. Kenney, F. S. Rosen, and E. Remold-O'Donnell. 2002. Wiskott-Aldrich syndrome in a female. Blood 100: 2763-2768.
28. Lutskiy, M. I., L. N. Jones, F. S. Rosen, and E. Remold-O'Donnell. 2002. An Alu-mediated deletion at Xp11.23 leading to Wiskott-Aldrich syndrome. Hum. Genet. 110: 515-519.
29. Wolff, J. A. 1967. Wiskott-Aldrich syndrome: clinical, immunologic, and pathologic observations. J. Pediatr. 70: 221-232.
30. Murphy, S., F. A. Oski, and F. H. Gardner. 1969. Hereditary thrombocytopenia with an intrinsic platelet defect. N. Engl. J. Med. 281: 857-862.
31. Hagemann, T. L., and S. P. Kwan. 1999. The identification and characterization of two promoters and the complete genomic sequence for the Wiskott-Aldrich syndrome gene. Biochem. Biophys. Res. Commun. 256: 104-109.
32. Prehoda, K. E., D. J. Lee, and W. A. Lim. 1999. Structure of the enabled/VASP homology 1 domain-peptide complex: a key component in the spatial control of actin assembly. Cell 97: 471-480.
33. Rong, S. B., and M. Vihinen. 2000. Structural basis of Wiskott-Aldrich syndrome causing mutations in the WH1 domain. J. Mol. Med. 78: 530-537.
34. Stewart, D. M., L. Tian, and D. L. Nelson. 1999. Mutations that cause the Wiskott-Aldrich syndrome impair the interaction of Wiskott-Aldrich syndrome protein (WASP) with WASP interacting protein. J. Immunol. 162: 5019-5020.
35. Moreau, V., F. Frischknecht, I. Reckmann, R. Vincentelli, G. Rabut, D. Stewart, and M. Way. 2000. A complex of N-WASP and WIP integrates signalling cascades that lead to actin polymerization. Nat. Cell Biol. 2: 441-448.
36. Nagy, E., and L. E. Maquat. 1998. A rule for termination-codon position within intron-containing genes: when nonsense affects RNA abundance. Trends Biochem. Sci. 23: 198-199.
37. Padgett, R. A., P. J. Grabowski, M. M. Konarska, S. Seiler, and P. A. Sharp. 1986. Splicing of messenger RNA precursors. Annu. Rev. Biochem. 55: 1119-1150.
38. Park, J. Y., M. Kob, A. P. Prodeus, F. S. Rosen, A. Shcherbina, and E. Remold-O'Donnell. 2004. Early deficit of lymphocytes in Wiskott-Aldrich syndrome: possible role of WASP in human lymphocyte maturation. Clin. Exp. Immunol. 136: 104-110.
39. Shcherbina, A., F. Candotti, F. S. Rosen, and E. Remold-O'Donnell. 2003. High incidence of lymphomas in a subgroup of Wiskott-Aldrich syndrome patients. Br. J. Haematol. 121: 529-530.
40. Haddad, E., E. Cramer, C. Riviere, P. Rameau, F. Louache, J. Guichard, D. L. Nelson, A. Fischer, W. Vainchenker, and N. Debili. 1999. The thrombocytopenia of Wiskott Aldrich syndrome is not related to a defect in proplatelet formation. Blood 94: 509-518.
41. Notarangelo, L. D., C. Mazza, S. Giliani, C. D'Aria, F. Gandellini, C. Ravelli, M. G. Locatelli, D. L. Nelson, and H. D. Ochs. 2002. Missense mutations of the WASP gene cause intermittent X-linked thrombocytopenia. Blood 99: 2268-2269.
42. Jin, Y., C. Mazza, J. R. Christie, S. Giliani, M. Fiorini, P. Mella, F. Gandellini, D. M. Stewart, Q. Zhu, D. L. Nelson, et al. 2004. Mutations of the Wiskott-Aldrich syndrome protein (WASP): hot spots, effect on transcription and translation and phenotype/genotype correlation. Blood 104: 4010-4019.
43. Imai, K., T. Morio, Y. Zhu, Y. Jin, S. Itoh, M. Kajiwara, J. Yata, S. Mizutani, H. D. Ochs, and S. Nonoyama. 2004. Clinical course of patients with WASP gene mutations. Blood 103: 456-464.